. Author manuscript; available in PMC: 2021 Dec 1.

Published in final edited form as: Biomark Neuropsychiatry. 2021 Jun 24;5:100038. doi: 10.1016/j.bionps.2021.100038

Table 5.

Effects Of Clozapine On mRNAs In Subjects With Schizophrenia

mRNA	On Clozapine	Not on Clozapine	Comparison Test
DNMT3A(m)	188.87±84.45 (n=13)	231.49±86.36 (n=15)	T=−1.36, df=1,26, P=.200
GAD1	0.469±0.296 (n=14)	0.102±0.156 (n=22)	T^L=5.70, df=1,34, P<.001
GAD67	0.195± 0.148 (n=12)	0.035± 0.062 (n=25)	MWU Z=3.76, P<.001
GAD25	0.388±0.497 (n=12)	0.006±0.007 (n=25)	T^L=4.01, df=1,35, P<.001
TET1	22.16 ±11.44 (n=14)	32.61±12.98 (n=22)	T=−2.46, df=1,34, P=.019
NR3C1-cus	170.50 ±73.00 (n=13)	130.61±36.40 (n=25)	T^U=1.85, df=1,15.2, P=.083
CNTNAP2	0.80 ± 1.83 (n=13)	0.07 ± 0.11 (n=23)	T^L= 4.12, df=34, P<.001
IMPA2	59.89 ± 36.73 (n=13)	26.23 ± 23.61 (n=23)	T^SR= 3.640, df=34, P=.001

Each umber represents Mean ± S.D. See legend to Table 4 for interpretation of symbols in comparison test results and interpretation of mean values. (m)=male subjects only.